Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications

被引:61
作者
Poulter, NR [1 ]
Chang, CL
Farley, TMM
Meirik, O
机构
[1] Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Clin Pharmacol, Cardiovasc Studies Unit, London W2 1PG, England
[2] WHO, UNDP UNFPA World Bank WHO Special Programme Res D, CH-1211 Geneva, Switzerland
关键词
D O I
10.1016/S0140-6736(99)03132-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.
引用
收藏
页码:1610 / 1610
页数:1
相关论文
共 5 条
[1]  
[Anonymous], 1995, J Clin Epidemiol, V48, P1513
[2]  
d'Arcangues C, 1999, CONTRACEPTION, V59, P31
[3]  
POULTER NR, 1995, LANCET, V346, P1575
[4]  
Poulter NR, 1996, LANCET, V348, P498
[5]  
Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1